• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在西班牙,将一个扩展的 DNA 和 RNA 组织测序面板纳入晚期黑色素瘤患者常规护理的可行性和影响。

Feasibility and Impact of Embedding an Extended DNA and RNA Tissue-Based Sequencing Panel for the Routine Care of Patients with Advanced Melanoma in Spain.

机构信息

Department of Pathology, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain.

August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Rosselló 149, 08036 Barcelona, Spain.

出版信息

Int J Mol Sci. 2024 Jun 25;25(13):6942. doi: 10.3390/ijms25136942.

DOI:10.3390/ijms25136942
PMID:39000050
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11241382/
Abstract

Targeted NGS allows a fast and efficient multi-gene analysis and the detection of key gene aberrations in melanoma. In this study, we aim to describe the genetic alterations in a series of 87 melanoma cases using the oncomine focus assay (OFA), relate these results with the clinicopathological features of the patients, and compare them with our previous study results in which we used a smaller panel, the oncomine solid tumor (OST) DNA kit. Patients diagnosed with advanced melanoma at our center from 2020 to 2022 were included and DNA and RNA were extracted for sequencing. Common mutated genes were (29%), (28%), , , and (5% each). Co-occurring mutations were detected in 29% of the samples, including with , , , , , or Amplifications and rearrangements were detected in 5% of cases. Only mutation showed a significant statistical association with sun exposure. For patients with a given genetic profile, the melanoma survival and recurrence-free survival rates were equivalent, but not for stage and LDH values. This expanded knowledge of molecular alterations has helped to more comprehensively characterize our patients and has provided relevant information for deciding the best treatment strategy.

摘要

靶向 NGS 可实现快速、高效的多基因分析,并检测黑色素瘤中的关键基因异常。在这项研究中,我们旨在使用 Oncomine Focus Assay(OFA)描述 87 例黑色素瘤病例中的遗传改变,将这些结果与患者的临床病理特征相关联,并与我们之前使用较小面板 Oncomine Solid Tumor(OST)DNA 试剂盒的研究结果进行比较。我们纳入了 2020 年至 2022 年在我们中心诊断为晚期黑色素瘤的患者,并提取 DNA 和 RNA 进行测序。常见的突变基因包括 (29%)、 (28%)、 、 、 和 (各 5%)。在 29%的样本中检测到共发生的突变,包括与 、 、 、 、 或 扩增和重排。仅 突变与阳光暴露有显著统计学关联。对于具有特定遗传特征的患者,黑色素瘤生存率和无复发生存率相当,但与分期和 LDH 值无关。对分子改变的这种扩展了解有助于更全面地描述我们的患者,并为决定最佳治疗策略提供了相关信息。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fd7/11241382/6a92dd177c5b/ijms-25-06942-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fd7/11241382/b7ffdf4ffc1b/ijms-25-06942-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fd7/11241382/d4087fb34891/ijms-25-06942-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fd7/11241382/6a92dd177c5b/ijms-25-06942-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fd7/11241382/b7ffdf4ffc1b/ijms-25-06942-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fd7/11241382/d4087fb34891/ijms-25-06942-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9fd7/11241382/6a92dd177c5b/ijms-25-06942-g003.jpg

相似文献

1
Feasibility and Impact of Embedding an Extended DNA and RNA Tissue-Based Sequencing Panel for the Routine Care of Patients with Advanced Melanoma in Spain.在西班牙,将一个扩展的 DNA 和 RNA 组织测序面板纳入晚期黑色素瘤患者常规护理的可行性和影响。
Int J Mol Sci. 2024 Jun 25;25(13):6942. doi: 10.3390/ijms25136942.
2
Melanoma with in-frame deletion of MAP2K1: a distinct molecular subtype of cutaneous melanoma mutually exclusive from BRAF, NRAS, and NF1 mutations.存在 MAP2K1 框内缺失的黑色素瘤:一种与 BRAF、NRAS 和 NF1 突变相互排斥的独特的皮肤黑色素瘤分子亚型。
Mod Pathol. 2020 Dec;33(12):2397-2406. doi: 10.1038/s41379-020-0581-5. Epub 2020 Jun 1.
3
Spectrum and Frequency of BRAF Mutations in Skin Melanomas in the Dalmatian Region of Croatia.克罗地亚达尔马提亚地区皮肤黑色素瘤中 BRAF 突变的谱和频率。
Acta Dermatovenerol Croat. 2024 Mar;32(1):75-76.
4
Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.原发性皮肤黑色素瘤的临床病理特征及突变分析
Am J Dermatopathol. 2015 May;37(5):389-97. doi: 10.1097/DAD.0000000000000241.
5
Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.NRAS 和 BRAF 基因突变状态与高危原发性黑色素瘤患者的黑色素瘤特异性生存之间的关联。
JAMA Oncol. 2015 Jun;1(3):359-68. doi: 10.1001/jamaoncol.2015.0493.
6
The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas.鉴定患者特异性突变揭示了大多数黑色素瘤患者存在双通路激活,而 BRAF/NRAS 野生型黑色素瘤中则存在激活的受体酪氨酸激酶。
Cancer. 2019 Feb 15;125(4):586-600. doi: 10.1002/cncr.31843. Epub 2018 Dec 18.
7
Clinical Application of Next-Generation Sequencing-Based Panel to Wild-Type Advanced Melanoma Identifies Key Oncogenic Alterations and Therapeutic Strategies.基于新一代测序的panel 在野生型晚期黑色素瘤中的临床应用确定了关键的致癌改变和治疗策略。
Mol Cancer Ther. 2020 Mar;19(3):937-944. doi: 10.1158/1535-7163.MCT-19-0457. Epub 2019 Dec 11.
8
Targeted next-generation sequencing of Japanese patients with sinonasal mucosal melanomas identifies frequent NRAS and CTNNB1 mutations.日本鼻腔鼻窦黏膜黑色素瘤患者的靶向下一代测序确定了频繁的NRAS 和 CTNNB1 突变。
Auris Nasus Larynx. 2024 Apr;51(2):313-319. doi: 10.1016/j.anl.2023.10.002. Epub 2023 Nov 10.
9
Spitz melanoma is a distinct subset of spitzoid melanoma.Spitz 黑色素瘤是 Spitz 样黑色素瘤的一个独特亚型。
Mod Pathol. 2020 Jun;33(6):1122-1134. doi: 10.1038/s41379-019-0445-z. Epub 2020 Jan 3.
10
Mutational profiling of acral melanomas in Korean populations.肢端黑色素瘤的突变特征分析在韩国人群中。
Exp Dermatol. 2017 Oct;26(10):883-888. doi: 10.1111/exd.13321. Epub 2017 May 3.

引用本文的文献

1
Detection of Circulating Tumor DNA in Liquid Biopsy: Current Techniques and Potential Applications in Melanoma.液体活检中循环肿瘤DNA的检测:当前技术及其在黑色素瘤中的潜在应用
Int J Mol Sci. 2025 Jan 20;26(2):861. doi: 10.3390/ijms26020861.

本文引用的文献

1
Molecular patterns of resistance to immune checkpoint blockade in melanoma.黑色素瘤免疫检查点阻断治疗耐药的分子模式。
Nat Commun. 2024 Apr 9;15(1):3075. doi: 10.1038/s41467-024-47425-y.
2
Role of Surgery in Metastatic Melanoma and Review of Melanoma Molecular Characteristics.手术在转移性黑色素瘤中的作用及黑色素瘤分子特征综述。
Cells. 2024 Mar 7;13(6):465. doi: 10.3390/cells13060465.
3
Molecular Frontiers in Melanoma: Pathogenesis, Diagnosis, and Therapeutic Advances.黑色素瘤的分子前沿:发病机制、诊断及治疗进展
Int J Mol Sci. 2024 Mar 4;25(5):2984. doi: 10.3390/ijms25052984.
4
Amplification of Mutant NRAS in Melanocytic Tumors With Features of Spitz Tumors.具有 Spitz 肿瘤特征的黑素细胞肿瘤中突变 NRAS 的扩增。
Mod Pathol. 2024 May;37(5):100469. doi: 10.1016/j.modpat.2024.100469. Epub 2024 Mar 10.
5
The Clinical, Genomic, and Transcriptomic Landscape of BRAF Mutant Cancers.BRAF 突变型癌症的临床、基因组和转录组学概况
Cancers (Basel). 2024 Jan 19;16(2):445. doi: 10.3390/cancers16020445.
6
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.序贯免疫治疗和靶向治疗转移性 BRAF V600 突变黑色素瘤:来自 II 期 SECOMBIT 试验的 4 年生存和生物标志物评估。
Nat Commun. 2024 Jan 2;15(1):146. doi: 10.1038/s41467-023-44475-6.
7
Androgen receptor is a determinant of melanoma targeted drug resistance.雄激素受体是黑色素瘤靶向药物耐药的决定因素。
Nat Commun. 2023 Oct 14;14(1):6498. doi: 10.1038/s41467-023-42239-w.
8
Systemic Therapy for Melanoma: ASCO Guideline Update.黑色素瘤的系统性治疗:ASCO 指南更新。
J Clin Oncol. 2023 Oct 20;41(30):4794-4820. doi: 10.1200/JCO.23.01136. Epub 2023 Aug 14.
9
Malignant Melanoma in Older Adults: Different Patient or Different Disease?老年恶性黑色素瘤:不同的患者还是不同的疾病?
Cureus. 2023 Feb 7;15(2):e34742. doi: 10.7759/cureus.34742. eCollection 2023 Feb.
10
Implementation of an NGS panel for clinical practice in paraffin-embedded tissue samples from locally advanced and metastatic melanoma patients.在局部晚期和转移性黑色素瘤患者的石蜡包埋组织样本中实施用于临床实践的二代测序(NGS)基因检测板。
Explor Target Antitumor Ther. 2020;1(2):101-108. doi: 10.37349/etat.2020.00006. Epub 2020 Apr 28.